If kininogen-1's utility as a biomarker is confirmed, it might be incorporated in routine screening in T1DM during pregnancy to assess the risk for development of diabetic nephropathy, associated complications including pre-term delivery and preeclampsia, or to develop early management strategies for such patients. This evidence concerns the gene KNG1 and diabetic kidney disease.